Catalent and Novo Holdings receive European Commission unconditional approval for pending transaction
Transaction expected to close towards the end of calendar year 2024 SOMERSET, N.J. & COPENHAGEN, Denmark — (BUSINESS WIRE) — Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo